SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-258063
Filing Date
2023-10-18
Accepted
2023-10-18 07:30:53
Documents
14
Period of Report
2023-10-18
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d570255d8k.htm   iXBRL 8-K 31671
2 EX-99.1 d570255dex991.htm EX-99.1 13342
6 GRAPHIC g570255dsp1.jpg GRAPHIC 33192
  Complete submission text file 0001193125-23-258063.txt   219613

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20231018.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20231018_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20231018_pre.xml EX-101.PRE 11261
8 EXTRACTED XBRL INSTANCE DOCUMENT d570255d8k_htm.xml XML 3353
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 231330924
SIC: 2835 In Vitro & In Vivo Diagnostic Substances